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Abstract. Boswellic acids (BAs) have long been considered 
as useful adjunct pharmacological agents for the treatment of 
patients with malignant brain tumors, notably glioblastoma. 
Two principal modes of action associated with BAs have been 
postulated: i) Anti‑inflammatory properties, which are useful 
for containing edema formation, and ii) intrinsic antitumor 
cell properties, with a hitherto ill‑defined mode of action. The 
present study assessed the effects of various BA derivatives 
on the viability and clonogenicity of a panel of nine long-term 
glioma cell lines and five glioma‑initiating cell lines, studied 
cell cycle progression and the mode of cell death induction, 
and explored potential synergy with temozolomide (TMZ) 
or irradiation. BA induced the concentration-dependent loss 
of viability and clonogenicity that was independent of tumor 
protein 53 status and O6-methylguanine DNA methyltrans-
ferase expression. The treatment of glioma cells with BA 
resulted in cell death induction, prior to or upon S phase entry, 
and exhibited features of apoptotic cell death. Synergy with 
irradiation or TMZ was detected at certain concentrations; 
however, the inhibitory effects were mostly additive, and never 
antagonistic. While the intrinsic cytotoxic properties of BA at 
low micromolecular concentrations were confirmed and the 
potential synergy with irradiation and TMZ was identified, 
the proximate pharmacodynamic target of BA remains to be 
identified.
Introduction
Boswellic acids (BAs) are gum resin extracts of Boswellia 
serrata (Indian frankincense) and other Boswellia species, 
which are mainly composed of volatile oils (5-15%), pure 
resin (55-66%) and mucus (12-23%) (1,2). The gum resin typi-
cally contains 30% BA (3); however, gum resins from various 
Boswellia species contrast in BA composition. For example, 
the gum resin of Boswellia serrata contains similar amounts 
of 11-keto-β-boswellic acid (KBA) and acetyl-KBA (AKBA) 
(3.0-4.7% and 2.2-2.9%, respectively); whereas, the gum resin 
of Boswellia carterii Birdw (African frankincense) contains 
decreased amounts of KBA (0.5%) compared with AKBA 
(3.3%). BAs are pentacyclic triterpenes, which may exist 
in an α- or β‑configuration (2,4). Various pharmacological 
studies indicate that β‑configurated derivatives exert stronger 
bioactivities compared with the respective α-isomers (5). 
Numerous Boswellia serrata products with varied composi-
tions have been subject to clinical investigation.
BAs have long been considered useful adjunct 
pharmacological agents for the treatment of patients with 
malignant gliomas (6) and, more recently, brain metas-
tasis (7). Two principal modes of action associated with BAs 
have been postulated. One theory suggests that BAs have 
anti-inflammatory properties, which are useful for containing 
edema formation in the context of growing brain tumors (6). 
The second theory proposes that BAs possess intrinsic anti-
tumor cell properties, which may decrease the tumor burden. 
The latter assumption has been largely based on cell culture 
studies, which includes a previous study from the Laboratory 
of Molecular Neuro-Oncology, Department of Neurology, 
University Hospital Zurich (Zurich, Switzerland) (8) and one 
in vivo study on the C6 rat model, published over a decade 
ago (9). BA-induced glioma cell death was previously 
characterized as apoptotic by morphology, but appeared not to 
involve caspase activation or be rescued by B-cell lymphoma 2 
family proteins (8).
The present study examined the effects of selected BA 
derivatives (α- and β‑configuration), with a focus on human 
glioma stem-like cells in vitro, and examined whether these 
agents act in synergy with temozolomide (TMZ) or irradiation, 
which are the standard choice of care in glioblastoma (10).
Materials and methods
Materials and cell lines. AKBA and β-BA were isolated from 
the resin of Boswellia serrata and purified by the Alpinia 
Institute (Alpinia Laudanum Institute of Phytopharmaceutical 
Sciences AG, Walenstadt, Switzerland). α-BA was purchased 
from Fluka (Sigma-Aldrich International GmbH, St. Gallen, 
Switzerland). Stock solutions of AKBA, α-BA and β-BA were 
prepared in 100% ethanol (MSD Merck Sharp & Dohme AG, 
Lucerne, Switzerland). Batch‑specific control of AKBA and 
β-BA was performed using high-pressure liquid chromatog-
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raphy (Alpinia Laudanum Institute of Phytopharmaceutical 
Sciences AG, Walenstadt, Switzerland). Aliquots were 
stored at 4˚C. Schering‑Plough TMZ was provided by Merck 
(Kenilworth, NJ, USA). A 200 mM stock solution of TMZ was 
prepared in dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO, 
USA) and stored at ‑20˚C.
The human glioma U87MG and T-98 G cell lines 
were purchased from the American Type Culture Collec-
tion (Manassas, VA, USA). The other long‑term cell lines 
(LTCs), including LN-18, LN-428, D-247MG, LN-319, A-172, 
LN-308 and LNT-229, were kindly provided by Professor 
N. de Tribolet (Lausanne, Switzerland). In addition to estab-
lished cell lines, the primary patient-derived glioma initiating 
cells (GICs) T-269, T-325, S-24, ZH-161 and ZH-305 were also 
used in the present study, which were isolated in the Labora-
tory of Molecular Neuro-Oncology, Department of Neurology, 
University Hospital Zurich, as previously described (11). 
LTCs were cultured in Dulbecco's modified Eagle's medium 
(Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) 
containing 10% fetal calf serum (FCS; Gibco; Thermo Fisher 
Scientific, Inc.) and 2 mM glutamine (Gibco; Thermo Fisher 
Scientific, Inc.). GIC were maintained in Neurobasal Medium® 
(Gibco; Thermo Fisher Scientific, Inc.) supplemented with 
2% B‑27 supplement (Gibco; Thermo Fisher Scientific, Inc.), 
2 mM glutamine, 20 ng/ml epidermal growth factor (Pepro-
Tech EC Ltd., London, UK), 20 ng/ml fibroblast growth factor 
(PeproTech EC Ltd.) and 32 international units/ml heparin 
(Sigma-Aldrich). For irradiation experiments, cells were 
irradiated in a Co-radiation source (60-Co Thermal Energy 
Systems; Sulzer AG, Winterthur, Switzerland) at 1, 3 and 
9 Gray (Gy) prior to the addition of BA derivatives for 72 h in 
serum-free medium (SFM; Gibco; Thermo Fisher Scientific, 
Inc.).
Acute viability assays. For LTCs, 10,000 cells/well were 
seeded in 96-well plates (TPP; Sigma-Aldrich) in full medium 
(Gibco; Thermo Fisher Scientific, Inc.) and allowed to attach 
for 24 h. The cells were then exposed to the BA derivatives at 
1.95-220.00 µM for 72 h in SFM. GICs were seeded using the 
aforementioned method in neurobasal medium (Gibco; Thermo 
Fisher Scientific, Inc.), incubated for 24 h and then exposed to 
BA derivatives for 72 h. A 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) assay was used to 
determine the metabolic activity of LTC and GIC. Briefly, MTT 
(Sigma-Aldrich) was dissolved in phosphate-buffered saline 
(PBS). Sodium dodecyl sulfate (10%; Fluka; Sigma-Aldrich) 
was used to dissolve the purple formazan. Absorbance 
was measured using the Infinite M200 spectrophotometer 
(Tecan Schweiz AG, Männedorf, Switzerland) at 540 nm. 
Solvent-treated cells (0.5% ethanol; Merck) were used as a 
reference for comparison. In addition, flow cytometry was used 
to assess the induction of apoptotic vs. necrotic cell death. The 
cells were harvested with accutase (Thermo Fisher Scientific, 
Inc.) and treated as indicated in Fig. 3 in SFM, washed in PBS, 
and resuspended in 10 mmol/l 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid/NaOH (pH 7.4), 140 mmol/l NaCl and 
2.5 mmol/l CaCl2. Fluorescein isothiocyanate (dilution, 1:100; 
Becton Dickinson AG, Allschwil, Switzerland) or Pacific 
Blue‑labelled Annexin V (AnxV; dilution, 1:100; BioLegend, 
Inc., San Diego, CA, USA) and propidium iodide (PI; 50 µg/ml; 
Sigma‑Aldrich) were added, and the fluorescence of unfixed 
cells in a total of 10,000 events per condition was recorded in 
a BD FACSVerseTM flow cytometer (Becton Dickinson AG). 
AnxV‑ or PI‑single or double‑positive cells were quantified 
using FlowJo Software (version 10.0.8; FlowJo LLC, Ashland, 
OR, USA).
Cell cycle analysis. The cells were treated as indicated in Fig. 3 
in SFM, harvested with accutase, fixed and permeabilized 
overnight in ice-cold 70% ethanol (Merck). The cells were 
washed twice with PBS. RNA was digested with RNase A 
(Gibco; Thermo Fisher Scientific, Inc.) and DNA was stained 
with PI (50 µg/ml; Sigma-Aldrich) containing 0.1% Triton 
X-100 (Sigma-Aldrich) to permeabilize the cells. Fluorescence 
was recorded in a BD FACSVerseTM flow cytometer (Becton 
Dickinson AG) and data was analyzed using FlowJo Software 
(version 10.0.8). Cells left of the G0/G1 peak were considered 
to have a DNA content of <2n, indicative of cell death. Aggre-
gated cells were gated out.
Clonogenicity and spherogenicity assays. For LTC, 
clonogenicity assays were performed by seeding 200 cells per 
well in 96-well plates that were allowed to adhere overnight in 
full medium. The cells were then exposed to BA derivatives 
at increasing concentrations in SFM, as indicated in Fig. 1. 
Subsequent to 24 h exposure, FCS was added to each well to 
a final concentration of 10%, and the assay was observed for 
at least 7 days. GICs were seeded at 200-400 cells per well in 
neurobasal medium and treated consecutively in the aforemen-
tioned manner in neurobasal medium. The cell metabolism of 
LTC and GIC was assessed by MTT assay.
Data analysis. Data are representative of experiments 
performed three times and the results were similar in all 
three experiments. Statistical analysis was performed using 
GraphPad Prism 5 software (GraphPad Software, Inc., 
La Jolla, CA, USA). The association between the sensitivity 
of cell lines to BA and p53 and MGMT expression was deter-
mined by Spearman's rank correlation coefficient. Synergy 
of irradiation or TMZ and BA derivatives was assessed by 
the fractional product method (12). Differences of 10% of 
observed vs. predicted (additive) effect were considered 
synergistic. P<0.05 was considered to indicate a statisti-
cally significant difference. The data are expressed as the 
mean ± standard error of the mean.
Results
Intrinsic BA activity against LTC and GIC glioma models. 
Three out of six major primary BA derivatives were tested 
for acute growth inhibitory and anti-clonogenic properties 
in a panel of nine LTC and five GIC models. Representative 
concentration and time response curves for selected BA 
derivatives are shown in Fig. 1A-C. The half maximal effective 
concentration (EC50) values in acute viability assays ranged 
between 1.1 and 314.4 µM in LTCs and between 42.1 and 
668.2 µM in GICs. AKBA showed the highest activity in six 
out of nine LTCs and four out of five GICs (Fig. 1D). In clono-
genic survival assays, the EC50 values ranged between 0.1 and 
88 µM in LTCs and 13.1 and 34.1 µM in GICs (Fig. 1E). The 
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EC50 values in acute viability and in clonogenic assays were 
correlated (r=0.80, P=0.0025). Therefore, the results of acute 
viability and clonogenic survival assays were similar overall, 
suggesting that acute cytotoxicity is largely responsible for the 
loss of clonogenicity or spherogenicity. Exposure to AKBA 
(19.5 µM), α-BA (22.0 µM) or β-BA (22.0 µM) inhibited sphere 
formation in ZH-161 (Fig. 2), T-269 or T-325 (data not shown).
In order to characterize the mode of growth inhibition in 
the short-term assays, the cell cycle progression of representa-
tive LTC (LN-319) or GIC (T-269) cells exposed to AKBA, 
α-BA and β‑BA were examined using flow cytometry at 72 h. 
In LTC, within the concentration and time ranges of these 
experiments, AKBA, α-BA and β-BA induced an increase of 
the sub-G1 fraction associated with a strong decrease in G1, 
Figure 1. Sensitivity of LTC and GIC to single BA derivatives (AKBA, α-BA and β-BA) in acute viability and in clonogenic survival assays. LN-319 LTCs 
or T-269 GICs were exposed to increasing drug concentrations and metabolic activity was assessed by MTT assay in (A) acute viability or (B) clonogenic 
survival assays. (C) Cells were exposed to drugs (AKBA, 1.95, 19.50 or 195.00 µM; α-BA and β-BA, 2.2, 22.0 or 220.0 µM) for 2, 4, 8, 12, 24, 48 or 72 h and 
then subjected to MTT assays. Data are expressed as mean and SEM (n=2). LTC (left, filled symbols) or GIC (right, open symbols) were exposed to BA in 
a concentration-dependent manner, and metabolic activity was assessed by MTT assay in (D) acute viability or (E) clonogenicity assays. EC50 values were 
calculated for each BA in every tested cell line. Representative results of two independent experiments are shown. The SEM was <15%. BA, boswellic acid; 
AKBA, acetyl-11-keto-β-boswellic acid; LTC, long-term cell line; GIC, glioma stem-like culture; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; EC50, half maximal effective concentration; SEM, standard error of the mean.
  A   B
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Figure 3. Mode of glioma cell death induced by AKBA, α-BA or β-BA. (A) LTC (LN-319) or GIC (T-269) were exposed to AKBA at 1.95, 19.50 or 195.00 µM 
and α-BA or β‑BA at 2.2, 22.0 or 220.0 µM for 72 h in serum‑free (LTC) or neurobasal medium (GIC), prior to flow cytometric cell cycle analysis. Cell 
distributions are shown as bar graphs (black, sub‑G1; dark grey, G0/G1; light grey, S; white, G2/M). (B) Viability of LN‑319 or T‑269 was determined by flow 
cytometry using A/PI staining following exposure to 19.5 µM (LN-319) or 195.0 µM (T-269) AKBA and 22 µM (LN-319) or 220 µM (T-269) α-BA or β-BA for 
3 or 12 and 72 h. Frequency plots of double-negative (A/PI-/-), single-positive (A/PI-/+ or A/PI+/-), or double-positive cells (A/PI+/+) are shown as bar graphs. 
BA, boswellic acid; AKBA, acetyl-11-keto-β‑boswellic acid; LTC, long‑term cell line; GIC, glioma stem‑like culture; A/PI, Annexin V/propidium iodide.
Figure 2. Inhibition of sphere formation by AKBA, α-BA or β-BA. ZH-161 (10,000 cells/well) were exposed to AKBA (19.5 µM), α-BA (22.0 µM) or β-BA 
(22.0 µM) and monitored for 168 h for sphere formation by phase contrast microscopy. Ethanol (1%) was included as solvent control. BA, boswellic acid; 
AKBA, acetyl-11-keto-β-boswellic acid.
  A
  B
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but only minor change in S or G2/M cells, indicating cell death 
induction prior to or upon S phase entry (Fig. 3A; upper panel). 
In GIC, neither a cell cycle arrest nor an induction of cell 
death prior or upon S phase entry was observed upon treat-
ment with BA. However, at the greatest drug concentrations, 
a trend towards increased sub-G1 and G2/M fractions was 
observed (Fig. 3A; lower panel). In addition, flow cytometry 
using AnxV/PI labeling for the early signs of apoptosis and 
the assessment of primary or secondary necrosis confirmed 
the induction of cell death, which evolved with early AnxV 
positivity following 3 h (GIC) and 12 h (LTC) incubation and 
resulted in secondary apoptotic events following 72 h incu-
bation, consistent with apoptotic cell death in LTC and GIC 
(Fig. 3B; left and right panels, respectively). A possible asso-
ciation between tumor protein 53 (p53) or O6-methylguanine 
DNA methyltransferase (MGMT) status and the sensitivity to 
BAs has also been identified (13,14). Of the LTCs, U87MG, 
LNT-229, A-172 and D247MG retain wild-type p53 function, 
determined by transcriptional activity (13), whereas LN-18 and 
T-98 G express MGMT (14). There was no association between 
the sensitivity of the cell lines to BA and p53 or MGMT status 
determined by the Spearman's rank correlation coefficient 
(p53, r=-0.056, P=0.88; MGMT, r=0.089, P=0.77) (13,14).
Synergistic activity of β‑BA with irradiation or TMZ. The sensi-
tivity of glioma cell lines to combination treatment with BA 
(AKBA, a-BA or β-BA) and TMZ (0, 100 or 500 µM) or irra-
diation (1, 3 or 9 Gy) was also examined in acute viability and 
clonogenic survival assays. Overall, the effects of combination 
therapy were mostly additive and never antagonistic, as defined 
by the fractional product method (data not shown) (12). Certain 
combinations of BA and TMZ or irradiation met the criteria for 
synergistic inhibition, as representatively shown in Fig. 4A-D. 
For instance, co-treatment with β-BA and TMZ (Fig. 4A and 
C) or irradiation (Fig. 4B and D) revealed synergistic effects 
at low BA concentrations (<EC50) in LN-319 cells in the two 
experimental set-ups. No such synergistic effects were observed 
for T-269 with either combination (data not shown).
Figure 4. Synergistic effects of BA and TMZ or irradiation. LN-319 cells were exposed for 72 h to β-BA (2.2 and 10.9 µM) (A) alone or (B) in combination with 
either TMZ (100 or 500 µM) or irradiation (1 or 3 Gray). Metabolic activity was assessed by MTT assay and the predicted vs. observed effect at 2.2 µM was 
compared using the fractional product method (12). Similar studies were performed as clonogenic survival assays, with β-BA (C) alone or (D) in combination 
with either TMZ (100 or 500 µM) or irradiation (1 or 3 Gray). Differences of 10% of observed vs. predicted (additive) effect were considered synergistic. Data 
are expressed as the mean ± standard error of the mean. BA, boswellic acid; TMZ, temozolomide; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide.
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Discussion
There is a great interest and requirement for novel therapeutic 
options for glioblastoma, including phytotherapeutic agents 
and agents targeting specifically tumor‑associated edema (6). 
BA derivatives have been used in this indication for over a 
decade, mostly in central European countries (2).
The present study confirms that BAs can exert significant 
cytotoxic and antiproliferative activities on a panel of LTCs 
and GICs (Fig. 1). These results extend the similar findings 
of previous studies on LTCs (8) to GIC models that were not 
available at the time. Sphere formation by GICs was inhibited 
in a concentration-dependent manner (Fig. 2). The biochemical 
mode of cytotoxic action of these compounds and associated 
proximate molecular targets remains unclear. Furthermore, the 
profound induction of cell death in glioma cell cultures may 
require certain concentrations of BA; whether the concentra-
tions can be achieved for prolonged time periods in an in vivo 
dosing setting remains uncertain. Several studies examining 
BA plasma and brain levels in rats following the oral admin-
istration of Boswellia serrate gum resin extracts (9,15,16) 
revealed that the brain demonstrates availability of the major 
BAs, with β-BA and α-BA exhibiting greatest and KBA and 
AKBA exhibiting the lowest levels (15). However, the achiev-
able BA levels described by Gerbeth et al (15) were decreased 
compared with the EC50 concentrations determined to be 
cytotoxic and antiproliferative for a panel of LTCs and GICs 
in the present study. This inconsistency may be due to the lack 
of radiological partial or complete responses in glioblastoma 
patients exposed to these agents.
From the current knowledge of glioma cells, it is unlikely 
that the candidate biochemical targets of BAs, including 
5-lipoxygenase, prostaglandin E synthase (PGES) or 
cathepsin G, are sufficiently essential for glioma cell viability 
to represent a lethal pharmacological target (2). However, to 
formally prove or disprove this hypothesis, the targets would 
require pharmacological or genetic deletion in order to assess 
whether the toxic effect of BAs may be reproduced.
Alternatively, in an in vivo setting, the targets of BA may be 
affected in glioma cells and in the infiltrating host cell popula-
tion, which contributes to tumor growth and is now considered 
a promising co-target in the treatment of gliomas (17). For 
example, the inhibition of cyclooxygenase-2, which regulates 
the production of prostaglandin E2 by PGES-1, was indicated 
to delay glioma development in a murine glioma model by 
inhibiting the development of myeloid derived suppressor 
cells (MDSCs) and the accumulation of the cells in the tumor 
microenvironment (18).
Therefore, anti-glioma effects may be inhibited by 
interfering with the infiltration of the tumor by MDSCs, 
microglial cells and macrophages, and with proinflammatory 
or potentially protumorigenic activities. To corroborate this 
assumption would require the establishment of an in vivo 
paradigm of BA, the control of glioma growth and the 
careful characterization of the host cell composition and 
inflammatory and immunological activity. The present data 
confirm that BAs possess intrinsic cytotoxic properties at 
low micromolecular concentrations and may potentially 
obtain synergy with irradiation and temozolomide. Therefore, 
BAs should be considered for the treatment of glioblastoma, 
although the proximate pharmacodynamic targets remain to 
be identified.
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